You are here

Generic Nausea Drug Offers New Therapy for Diabetic Nerve Pain

Synthetic cannabinoid mimics chemical compounds of cannabis (Oct. 30)

A study conducted in Canada at the University of Calgary’s Hotchkiss Brain Institute has provided evidence to support the use of the generic drug nabilone for the treatment of diabetic neuropathy, which affects about half of all diabetic patients.

The researchers enrolled 60 patients in a 12-week placebo-controlled clinical study. The patients receiving nabilone reported less pain and an improvement in sleep and anxiety compared with those taking placebo.

The results were published in the October issue of Pain.

Nabilone is a synthetic cannabinoid that mimics some of the chemical compounds of cannabis. It is approved for use by the FDA and Health Canada, and is currently used to treat nausea and vomiting in chemotherapy patients.

“This study is a further demonstration of the potential medical benefits of cannabinoids in a difficult pain condition,” said Dr. Mark Ware.

Source: Hotchkiss Brain Institute, October 30, 2012.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs